Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease.

[1]  C. Meijer,et al.  Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. , 2005, The Journal of infectious diseases.

[2]  Richard J. H. Smith,et al.  Recurrent respiratory papillomatosis: pathogenesis to treatment , 2005, Current opinion in otolaryngology & head and neck surgery.

[3]  K. Shah,et al.  Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention , 2005 .

[4]  S. Franceschi,et al.  Human Papillomavirus Genotype Distribution in Low-Grade Cervical Lesions: Comparison by Geographic Region and with Cervical Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[5]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[6]  Alisha Johnston,et al.  Sexually transmitted infections in New Zealand in 2003. , 2005, The New Zealand medical journal.

[7]  C. Lacey.  Therapy for genital human papillomavirus-related disease. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[8]  C. Lacey,et al.  The interrelation of demographic and geospatial risk factors between four common sexually transmitted diseases , 2005, Sexually Transmitted Infections.

[9]  W. Klaskala,et al.  Epidemiological characteristics of human herpesvirus‐8 infection in a large population of antenatal women in Zambia , 2005, Journal of medical virology.

[10]  T. R. Broker,et al.  Recurrent Respiratory Papillomatosis: A Longitudinal Study Comparing Severity Associated With Human Papilloma Viral Types 6 and 11 and Other Risk Factors in a Large Pediatric Population , 2004, The Laryngoscope.

[11]  J. Field,et al.  Integration of Human Papillomavirus Type 11 in Recurrent Respiratory Papilloma‐Associated Cancer , 2004, The Laryngoscope.

[12]  P. Langley,et al.  The costs of treating external genital warts in England and Wales: a treatment pattern analysis , 2004, International journal of STD & AIDS.

[13]  Claude Fauquet,et al.  Classification of papillomaviruses. , 2004, Virology.

[14]  K. Shah,et al.  Clinical course of recurrent respiratory papillomatosis in Danish children. , 2004, Archives of otolaryngology--head & neck surgery.

[15]  B. Steinberg,et al.  Latent human papillomavirus infection is comparable in the larynx and trachea , 2004, Journal of medical virology.

[16]  Richard A. Moore,et al.  Therapeutic immunisation with COPV early genes by epithelial DNA delivery. , 2003, Virology.

[17]  I. Byren,et al.  Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts , 2003, Sexually transmitted infections.

[18]  E. Dasbach,et al.  The health and economic burden of genital warts in a set of private health plans in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  K. Shah,et al.  Condyloma in Pregnancy Is Strongly Predictive of Juvenile‐Onset Recurrent Respiratory Papillomatosis , 2003, Obstetrics and gynecology.

[20]  L. Koutsky,et al.  Do Condoms Prevent Genital HPV Infection, External Genital Warts, or Cervical Neoplasia?: A Meta-Analysis , 2002, Sexually transmitted diseases.

[21]  R. Greenblatt,et al.  The Impact of HIV Infection and Immunodeficiency on Human Papillomavirus Type 6 or 11 Infection and on Genital Warts , 2002, Sexually transmitted diseases.

[22]  Anne M Johnson,et al.  Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection , 2001, The Lancet.

[23]  Wendy Macdowall,et al.  Sexual behaviour in Britain: early heterosexual experience , 2001, The Lancet.

[24]  R. Hayes,et al.  The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania , 2001, Sexually transmitted infections.

[25]  C. Lacey,et al.  European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts , 2000, Sexually Transmitted Infections.

[26]  W. Reeves,et al.  Initial Results From the National Registry for Juvenile-Onset Recurrent Respiratory Papillomatosis , 1999 .

[27]  K. Sherman,et al.  Risk Factors for Incident and Recurrent Condylomata Acuminata Among Women: A Population‐Based Study , 1998, Sexually transmitted diseases.

[28]  S. Kjaer,et al.  History of Genital Warts in 10,838 Women 20 to 29 Years of Age From the General Population: Risk Factors and Association With Papanicolaou Smear History , 1997, Sexually transmitted diseases.

[29]  C. Derkay.  Task force on recurrent respiratory papillomas. A preliminary report. , 1995, Archives of otolaryngology--head & neck surgery.

[30]  S. Buchbinder,et al.  The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. , 1995, American journal of epidemiology.

[31]  S. Leeder,et al.  A population based study , 1993, The Medical journal of Australia.

[32]  J. Cuzick,et al.  EFFECT OF CIGARETTE SMOKING ON CERVICAL EPITHELIAL IMMUNITY: A MECHANISM FOR NEOPLASTIC CHANGE? , 1988, The Lancet.

[33]  L. Gissmann,et al.  Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. , 1985, The Journal of investigative dermatology.

[34]  M. Salkie,et al.  TESTS OF LIVER FUNCTION , 1974 .

[35]  A. Ferenczy,et al.  Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. , 1998, Archives of dermatology.